{"id":9809,"date":"2026-03-31T00:34:22","date_gmt":"2026-03-30T21:34:22","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9809"},"modified":"2026-03-31T00:34:22","modified_gmt":"2026-03-30T21:34:22","slug":"catheter-directed-therapy-vs-anticoagulation-in-intermediate-risk-pe-hi-peitho","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/catheter-directed-therapy-vs-anticoagulation-in-intermediate-risk-pe-hi-peitho\/","title":{"rendered":"Catheter-Directed Therapy vs Anticoagulation in Intermediate-Risk PE (HI-PEITHO):"},"content":{"rendered":"<p><span>Catheter-Directed Therapy vs Anticoagulation in Intermediate-Risk PE (HI-PEITHO):<\/span><\/p>\n<p><span>Early Benefit\u2026 in Selected Patients (Follow-up: 7 days)<\/span><br \/>\n<span>\u2022 \u2193 Primary events 61%(No \u2191 major bleeding. No mortality difference<\/span><\/p>\n<p><span>\u00a0Only in carefully selected patients)<\/span><\/p>\n<p><span>Selection Basis:<\/span><br \/>\n<span>\u2022 RV dysfunction (RV\/LV \u2265 1.0)<\/span><br \/>\n<span>\u2022 \u2191 Troponin<\/span><br \/>\n<span>\u2022 \u22652 signs of cardiorespiratory stress<\/span><br \/>\n<span>\u00a0Closest to Category D (pre-shock)<\/span><\/p>\n<p><span>Source<\/span><br \/>\n<span>\u2022 TCTMD \u2014 ACC 2026 Conference Coverage<\/span><br \/>\n<span>\u2022 NEJM (simultaneous publication)<\/span><\/p>\n<p><span>\u00a0Link (direct):<\/span><br \/>\n<a href=\"https:\/\/www.tctmd.com\/news\/hi-peitho-catheter-directed-therapy-bests-anticoagulation-intermediate-risk-pe\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.tctmd.com\/news\/hi-peitho-catheter-directed-therapy-bests-anticoagulation-intermediate-risk-pe&amp;source=gmail&amp;ust=1774992610400000&amp;usg=AOvVaw0cdNoYYsk5cGBYeRxv9bUY\" rel=\"noopener\">https:\/\/www.tctmd.com\/news\/hi-<wbr \/>peitho-catheter-directed-<wbr \/>therapy-bests-anticoagulation-<wbr \/>intermediate-risk-pe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Catheter-Directed Therapy vs Anticoagulation in Intermediate-Risk PE (HI-PEITHO): Early Benefit\u2026 in Selected Patients (Follow-up: 7 days) \u2022 \u2193 Primary events 61%(No \u2191 major bleeding. No mortality difference \u00a0Only in carefully selected patients) Selection Basis: \u2022 RV dysfunction (RV\/LV \u2265 1.0) \u2022 \u2191 Troponin \u2022 \u22652 signs of cardiorespiratory stress \u00a0Closest to Category D (pre-shock) Source [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9809","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9809"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9809\/revisions"}],"predecessor-version":[{"id":9810,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9809\/revisions\/9810"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}